in the first three phases of thrombolysis and angioplasty in myocardial infarction ( tami ) multicenter trials , 708 patients received intravenous recombinant tissue-type plasminogen activator ( rt-pa ) and underwent detailed assessment of clinical , angiographic and ventriculographic outcomes .
C0027051
tami
C0032143
recombinant tissue